Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/21750
Title: A harmonized longitudinal biomarkers and cognition database for assessing the natural history of preclinical Alzheimer's disease from young adulthood and for designing prevention trials.
Austin Authors: Xiong, Chengjie;Luo, Jingqin;Agboola, Folasade;Li, Yan;Albert, Marilyn;Johnson, Sterling C;Koscik, Rebecca L;Masters, Colin L ;Soldan, Anja;Villemagne, Victor L ;Li, Qiao-Xin;McDade, Eric M;Fagan, Anne M;Massoumzadeh, Parinaz;Benzinger, Tammie;Hassenstab, Jason;Bateman, Randall J;Morris, John C
Affiliation: Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD, USA
Department of Radiology, Washington University School of Medicine, St. Louis, MO, USA
Departments of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO, USA
The Florey Institute, University of Melbourne, Melbourne, Australia
Department of Molecular Imaging and Therapy, Austin Health, Heidelberg, Victoria, Australia
Department of Medicine, University of Melbourne, Melbourne, Australia
Division of Biostatistics, Washington University School of Medicine, St. Louis, MO, USA
Knight Alzheimer's Disease Research Center, Washington University School of Medicine, St. Louis, MO, USA
Division of Public Health Sciences, Department of Surgery, Washington University School of Medicine, St. Louis, MO, USA
Siteman Cancer Center Biostatistics Core Washington University School of Medicine, St. Louis, MO, USA
Department of Neurology, Washington University School of Medicine, St. Louis, MO, USA
Wisconsin Alzheimer's Institute and Alzheimer's Disease Research Center, University of Wisconsin-Madison School of Medicine and Public Health, Madison, WI, USA
Geriatric Research Education and Clinical Center, William S Middleton Veterans Memorial Hospital, Madison, WI, USA
Issue Date: Nov-2019
metadata.dc.date: 2019-09-07
Publication information: Alzheimer's & Dementia 2019; 15(11): 1448-1457
Abstract: Large longitudinal biomarkers database focusing on middle age is needed for Alzheimer's disease (AD) prevention. Data for cerebrospinal fluid analytes, molecular imaging of cerebral fibrillar β-amyloid with positron emission tomography, magnetic resonance imaging-based brain structures, and clinical/cognitive outcomes were harmonized across eight AD biomarker studies. Statistical power was estimated. The harmonized database included 7779 participants with clinical/cognitive data: 3542 were 18∼65 years at the baseline, 5865 had longitudinal cognitive data for a median of 4.7 years, 2473 participated in the cerebrospinal fluid studies (906 had longitudinal data), 2496 participated in the magnetic resonance imaging studies (1283 had longitudinal data), and 1498 participated in the positron emission tomography amyloid studies (849 had longitudinal data). The database provides adequate power for detecting early biomarker changes, and demonstrates the feasibility of AD prevention trials on middle-aged individuals. The harmonized database is an optimum resource to design AD prevention trials decades before symptomatic onset.
URI: http://ahro.austin.org.au/austinjspui/handle/1/21750
DOI: 10.1016/j.jalz.2019.06.4955
PubMed URL: 31506247
Type: Journal Article
Subjects: Alzheimer disease
Amyloid imaging with positron emission tomography (PET) using the [(11)C] benzothiazole tracer
Biomarkers
Cerebrospinal fluid (CSF)
Magnetic resonance imaging (MRI) volumetrics
Pittsburgh Compound-B (PIB)
Preclinical stages
Prevention trials
Appears in Collections:Journal articles

Show full item record

Page view(s)

28
checked on Dec 8, 2022

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.